[HTML][HTML] Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
G Finazzi, V De Stefano, T Barbui - Blood Cancer Journal, 2018 - nature.com
Myeloproliferative neoplasms (MPNs) are a leading cause of splanchnic vein thrombosis
(SVT). SVT is observed in all MPNs and frequently affects young patients. Therapy should …
(SVT). SVT is observed in all MPNs and frequently affects young patients. Therapy should …
Splanchnic vein thrombosis associated with myeloproliferative neoplasms
D Tremblay, A Winters, JD Beckman, L Naymagon… - Thrombosis …, 2022 - Elsevier
Splanchnic vein thrombosis (SVT) in the setting of myeloproliferative neoplasm (MPN) is a
unique clinical entity that requires close interdisciplinary coordination for proper diagnosis …
unique clinical entity that requires close interdisciplinary coordination for proper diagnosis …
Vascular diseases in patients with chronic myeloproliferative neoplasms–impact of comorbidity
H Frederiksen, S Szépligeti, M Bak… - Clinical …, 2019 - Taylor & Francis
Background Patients with chronic myeloproliferative neoplasms (MPNs), including essential
thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are at high …
thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are at high …
[HTML][HTML] Prefibrotic myelofibrosis: treatment algorithm 2018
G Finazzi, AM Vannucchi, T Barbui - Blood cancer journal, 2018 - nature.com
Prefibrotic myelofibrosis (pre-PMF) is a distinct entity among chronic myeloproliferative
neoplasm diagnosed according to the revised 2016 WHO classification. The clinical picture …
neoplasm diagnosed according to the revised 2016 WHO classification. The clinical picture …
[PDF][PDF] 骨髓增殖性肿瘤血栓事件的治疗现状
刘苗苗, 郭涛 - 临床血液学杂志, 2021 - lcxy.whuhzzs.com
专家简介: 郭涛, 华中科技大学同济医学院附属协和医院血液科主任医师, 博士生导师.
担任中国医师协会血液科医师分会委员, 海峡两岸医药卫生交流协会血液病学专业委员会副主任 …
担任中国医师协会血液科医师分会委员, 海峡两岸医药卫生交流协会血液病学专业委员会副主任 …
[HTML][HTML] Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy
S Brkic, S Stivala, A Santopolo, J Szybinski, S Jungius… - Leukemia, 2021 - nature.com
Myeloproliferative neoplasms (MPN) show dysregulated JAK2 signaling. JAK2 inhibitors
provide clinical benefits, but compensatory activation of MAPK pathway signaling impedes …
provide clinical benefits, but compensatory activation of MAPK pathway signaling impedes …
Clinical features and long-term outcomes of a Pan-Canadian cohort of adolescents and young adults with myeloproliferative neoplasms: a Canadian MPN Group …
JT England, N Szuber, S Sirhan, T Dunne, S Cerquozzi… - Leukemia, 2024 - nature.com
Myeloproliferative neoplasms (MPNs) are a group of chronic hematologic malignancies that
lead to morbidity and early mortality due to thrombotic complications and progression to …
lead to morbidity and early mortality due to thrombotic complications and progression to …
Givinostat: an emerging treatment for polycythemia vera
HT Chifotides, P Bose, S Verstovsek - Expert opinion on …, 2020 - Taylor & Francis
Introduction Polycythemia vera (PV), a Philadelphia chromosome-negative
myeloproliferative neoplasm, is characterized by panmyelosis, pancytosis, and a JAK2 …
myeloproliferative neoplasm, is characterized by panmyelosis, pancytosis, and a JAK2 …
Normal life expectancy for polycythemia vera (PV) patients is possible
G Abu-Zeinah, RT Silver, K Abu-Zeinah, JM Scandura - Leukemia, 2022 - nature.com
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by
shortened survival due to potentially fatal complications including thrombosis, and …
shortened survival due to potentially fatal complications including thrombosis, and …
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
NA Podoltsev, R Wang, RM Shallis… - Cancer …, 2023 - Wiley Online Library
Background Polycythemia vera (PV) and essential thrombocythemia (ET) are linked to
increased risk of cardiovascular morbidity and mortality. In addition to the reduction in of …
increased risk of cardiovascular morbidity and mortality. In addition to the reduction in of …